These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32791881)

  • 1. Symptom Burden and Unmet Needs in Malignant Pleural Mesothelioma: Exploratory Analyses From the RESPECT-Meso Study.
    Hoon SN; Lawrie I; Qi C; Rahman N; Maskell N; Forbes K; Gerry S; Monterosso L; Chauhan A; Brims FJH
    J Palliat Care; 2021 Apr; 36(2):113-120. PubMed ID: 32791881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
    Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
    BMC Cancer; 2018 Mar; 18(1):350. PubMed ID: 29587685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.
    Brims F; Gunatilake S; Lawrie I; Marshall L; Fogg C; Qi C; Creech L; Holtom N; Killick S; Yung B; Cooper D; Stadon L; Cook P; Fuller E; Walther J; Plunkett C; Bates A; Mackinlay C; Tandon A; Maskell NA; Forbes K; Rahman NM; Gerry S; Chauhan AJ;
    Thorax; 2019 Apr; 74(4):354-361. PubMed ID: 30661019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.
    Gunatilake S; Brims FJ; Fogg C; Lawrie I; Maskell N; Forbes K; Rahman N; Morris S; Ogollah R; Gerry S; Peake M; Darlison L; Chauhan AJ
    Trials; 2014 Sep; 15():367. PubMed ID: 25238873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
    Moore A; Bennett B; Taylor-Stokes G; McDonald L; Daumont MJ
    BMC Cancer; 2022 Jun; 22(1):693. PubMed ID: 35739480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma.
    Mollberg NM; Vigneswaran Y; Kindler HL; Warnes C; Salgia R; Husain AN; Vigneswaran WT
    Ann Thorac Surg; 2012 Oct; 94(4):1086-92. PubMed ID: 22921241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma.
    Cleeland CS; Keating KN; Cuffel B; Elbi C; Siegel JM; Gerlinger C; Symonds T; Sloan JA; Dueck AC; Bottomley A; Wang XS; Williams LA; Mendoza TR
    Sci Rep; 2024 Jun; 14(1):14839. PubMed ID: 38937473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced Symptom Management System for Patients with Malignant Pleural Mesothelioma (ASyMSmeso): Mixed Methods Study.
    Maguire R; Connaghan J; Arber A; Klepacz N; Blyth KG; McPhelim J; Murray P; Rupani H; Chauhan A; Williams P; McNaughton L; Woods K; Moylan A
    J Med Internet Res; 2020 Nov; 22(11):e19180. PubMed ID: 33180025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma.
    Vigneswaran WT; Kircheva DY; Rodrigues AE; Watson S; Celauro AD; Rose B; Kindler HL; Husain AN
    World J Surg; 2018 Apr; 42(4):1036-1045. PubMed ID: 28948332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician requests by patients with malignant pleural mesothelioma in Japan.
    Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
    BMC Cancer; 2019 Apr; 19(1):383. PubMed ID: 31023248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
    Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
    J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
    Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
    Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.
    Gelhorn HL; Skalicky AM; Balantac Z; Eremenco S; Cimms T; Halling K; Hollen PJ; Gralla RJ; Mahoney MC; Sexton C
    Support Care Cancer; 2018 Jul; 26(7):2229-2238. PubMed ID: 29392480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
    Warby A; Dhillon HM; Kao S; Vardy JL
    Support Care Cancer; 2019 Sep; 27(9):3509-3519. PubMed ID: 30684047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
    Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
    J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
    Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
    Williams LA; Whisenant MS; Mendoza TR; Haq S; Keating KN; Cuffel B; Cleeland CS
    Qual Life Res; 2018 Dec; 27(12):3229-3241. PubMed ID: 30187393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.
    Schwartz RM; Lieberman-Cribbin W; Wolf A; Flores RM; Taioli E
    BMC Cancer; 2018 Nov; 18(1):1188. PubMed ID: 30497433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.